title: Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline.
abstract: BACKGROUND
  The N-methyl-d-aspartate (NMDA) receptor antagonist phencyclidine (PCP)-induced cognitive deficits have been used as an animal model for schizophrenia. This study was undertaken to determine whether the antibiotic drug minocycline could improve PCP-induced cognitive deficits in mice.
  
  
  METHODS
  Saline (10 ml/kg/day, s.c., once daily on day 1-5, 8-12) or PCP (10 mg/kg/day, s.c., once daily on day 1-5, 8-12) were administered to mice for 10 days. Subsequently, vehicle (10 ml/kg/day, i.p.) or minocycline (4.0 or 40 mg/kg/day, i.p.) was injected for 14 consecutive days. One day after the final injection, a novel object recognition test was performed.
  
  
  RESULTS
  PCP-induced cognitive deficits in mice were significantly improved by subsequent subchronic (14 days) administration of minocycline (40 mg/kg), but not minocycline (4.0 mg/kg).
  
  
  CONCLUSIONS
  This study suggests that minocycline could be a potential therapeutic drug for cognitive deficits in schizophrenic patients.
authors: Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan.
authors: Yuko
authors: Y
authors: Fujita
authors: Tamaki
authors: T
authors: Ishima
authors: Shinsui
authors: S
authors: Kunitachi
authors: Hiroko
authors: H
authors: Hagiwara
authors: Lin
authors: L
authors: Zhang
authors: Masaomi
authors: M
authors: Iyo
authors: Kenji
authors: K
authors: Hashimoto
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects*; D003072:Cognition Disorders / Q000139:chemically induced* / Q000188:drug therapy*; D004334:Drug Administration Schedule; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005106:Exploratory Behavior / Q000187:drug effects; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008911:Minocycline / Q000494:pharmacology / Q000627:therapeutic use*; D010622:Phencyclidine / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology
chemical_list: D000900:Anti-Bacterial Agents; D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D008911:Minocycline; D010622:Phencyclidine